8% Rise in the demand for biotech, pharma profiles most in demand in March 2018

It’s a very good news for professional from biotech, pharma sector as their market demand got a rise. This growth registered in March 2018, by the recruitment index in the last four months.  And there is a rise of 9% in overall talent demand as compared to last year (from March 2017- March 2018).

TimesJobs’ recruitment portal RecruiteX generates a monthly hiring trend report for the talents.
RecruiteX showed in the report that key industries and functional areas posted a rise in talent requirement and contributed to this highest rise of 8% in hiring activities in March 2018. Talent demand was at the peak for talents with 10-20 years of experience.

If we consider a rise in terms of the Industries, then construction industry experiences maximum talent growth.

13% rise is registered in hiring for the construction sector in March 2018, followed by 12% rise in talent demand in the petrochemicals sector in India. 12% rise in talent demand also saw for the infrastructure sector.

According to the Ramathreya Krishnamurthi words, Business Head, TimesJobs & TechGig We can hope that this momentum sustains for the coming months too due to the Fresh policies and new projects that resulted in this increased talent demand.

If we consider functional area analysis then Biotech, pharma profiles are in demand. 21% of rising witnessed for the Biotechnology and pharma profiles in March 2018. Followed by IT/Telecom professionals which witnessed a 10% rise in talent demand. Engineers also witnessed 10% rise in demand as per month-on-month analysis.

Timesjobs is considered as a platform to help competent professionals to enhance their career growth. It currently has over 25 million registered jobseekers across the board and more than 60 million page views every month, it is the most preferred career portal among ambitious and talented professionals who want to make smarter career decisions that accelerate their career progression.

Related Posts

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta, a UK-based clinical stage biotech, is differentiated clinical-stage oncology specialist, increasingly defined by continuing progress with its second-generation pre|CISION tumour-activated Peptide Drug Conjugate (PDC) platform. The lead Gen Two…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Puresta launches EVERQ, AI-powered skin-health platform

Puresta launches EVERQ, AI-powered skin-health platform

Stem cell therapy for autism only in approved clinical trials: Centre

Stem cell therapy for autism only in approved clinical trials: Centre